Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ACI-7104.056 at Dose A · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Early PD subjects receive placebo at pre-defined time points over 74 weeks. |
| ACI-7104.056 at Dose A | EXPERIMENTAL | Early PD subjects receive dose A of ACI-7104.056 at pre-defined time points over 74 weeks. |
| ACI-7104.056 at Dose B (optional) | EXPERIMENTAL | Early PD subjects receive dose B of ACI-7104.056 at pre-defined time points over 74 weeks. This arm is optional. |
| ACI-7104.056 at Dose C (optional) | EXPERIMENTAL | Early PD subjects receive dose C of ACI-7104.056 at pre-defined time points over 74 weeks. This arm is optional. |
| Name | Type | Description |
|---|---|---|
| Placebo | BIOLOGICAL | The placebo is a solution matching the study treatment formulation. |
| ACI-7104.056 at Dose A | BIOLOGICAL | The study treatment (ACI-7104.056) consists of an adjuvanted protein peptide conjugate vaccine. |
| ACI-7104.056 at Dose B (optional) | BIOLOGICAL | The study treatment (ACI-7104.056) consists of an adjuvanted protein peptide conjugate vaccine. |
| ACI-7104.056 at Dose C (optional) | BIOLOGICAL | The study treatment (ACI-7104.056) consists of an adjuvanted protein peptide conjugate vaccine. |
Inclusion criteria: 1. Confirmed diagnosis of clinically established early PD using the modified Movement Disorder Society criteria, after excluding any other known or suspected cause of PD. The presence of motor symptoms should not be of more than 2 years at screening. 2. Monotherapy treatment wit...
Top 20 of 22 competitors
ACI-7104.056 is an investigational monoclonal antibody being developed for the treatment of early stages of Parkinson's Disease. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities. The drug is being studied in patients with early-onset Parkinson's Disease.
ACI-7104.056 is a monoclonal antibody designed to target a specific protein involved in Parkinson's Disease pathology. As a monoclonal antibody, it is intended to bind to its target and modulate the disease process. The exact molecular target has not been disclosed in available information.
ACI-7104.056 is being developed by AC Immune SA, a biopharmaceutical company listed on the NASDAQ under the ticker symbol ACIU. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug for Parkinson's Disease.
ACI-7104.056 is currently in Phase 2 clinical development. It is an investigational drug and has not yet received regulatory approval. The ongoing Phase 2 trial is active but not recruiting participants, indicating that enrollment has been completed and the study is ongoing.
ACI-7104.056 is being evaluated in a Phase 2 clinical trial with the identifier NCT06015841. This randomized, double-blind, placebo-controlled study is assessing the effects of the drug in patients with early stages of Parkinson's Disease. The trial has an enrollment of 150 participants and is being conducted in Germany, Spain, and the United Kingdom.
ACI-7104.056 is the specific drug candidate being studied in clinical trials. It is a monoclonal antibody developed by AC Immune SA for Parkinson's Disease. The name ACI-7104.056 may refer to a particular formulation or version of the drug, but no alternative names have been disclosed in available information.